Pharmacological correction of misfolding of ABC proteins☆
暂无分享,去创建一个
[1] David Y. Thomas,et al. Carbamazepine as a Novel Small Molecule Corrector of Trafficking-impaired ATP-sensitive Potassium Channels Identified in Congenital Hyperinsulinism* , 2013, The Journal of Biological Chemistry.
[2] T. Uchiumi,et al. Mutation and functional analysis of ABCC2/multidrug resistance protein 2 in a Japanese patient with Dubin–Johnson syndrome , 2013, Hepatology research : the official journal of the Japan Society of Hepatology.
[3] G. Leftheriotis,et al. The molecular and physiological roles of ABCC6: more than meets the eye , 2012, Front. Gene..
[4] C. Cremer,et al. Localization Microscopy (SPDM) Reveals Clustered Formations of P-Glycoprotein in a Human Blood-Brain Barrier Model , 2012, PloS one.
[5] D. Cassio,et al. Successful mutation-specific chaperone therapy with 4-phenylbutyrate in a child with progressive familial intrahepatic cholestasis type 2. , 2012, Journal of hepatology.
[6] Tudor I. Oprea,et al. A Novel Flow Cytometric HTS Assay Reveals Functional Modulators of ATP Binding Cassette Transporter ABCB6 , 2012, PloS one.
[7] Simon C Watkins,et al. Pharmacological Rescue of the Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Detected by Use of a Novel Fluorescence Platform , 2012, Molecular medicine.
[8] J. Schuetz,et al. ABC transporters and their role in nucleoside and nucleotide drug resistance. , 2012, Biochemical pharmacology.
[9] L. Wojnowski,et al. Functional characterization of protein variants of the human multidrug transporter ABCC2 by a novel targeted expression system in fibrosarcoma cells , 2012, Human mutation.
[10] C. Ehrhardt,et al. New fluorescent bile acids: synthesis, chemical characterization, and disastereoselective uptake by Caco-2 cells of 3-deoxy 3-NBD-amino deoxycholic and ursodeoxycholic acid. , 2012, Bioorganic & medicinal chemistry.
[11] A S Verkman,et al. CFTR: folding, misfolding and correcting the ΔF508 conformational defect. , 2012, Trends in molecular medicine.
[12] K. Du,et al. Correction of Both NBD1 Energetics and Domain Interface Is Required to Restore ΔF508 CFTR Folding and Function , 2012, Cell.
[13] V. Haufroid,et al. Functional defect caused by the 4544G>A SNP in ABCC2: potential impact for drug cellular disposition , 2011, Pharmacogenetics and genomics.
[14] John M. Knapp,et al. Cyanoquinolines with Independent Corrector and Potentiator Activities Restore ΔPhe508-Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channel Function in Cystic Fibrosis , 2011, Molecular Pharmacology.
[15] T. Ishikawa,et al. Ubiquitin-mediated proteasomal degradation of ABC transporters: a new aspect of genetic polymorphisms and clinical impacts. , 2011, Journal of pharmaceutical sciences.
[16] Wayne F. Patton,et al. Sensitive and Specific Fluorescent Probes for Functional Analysis of the Three Major Types of Mammalian ABC Transporters , 2011, PloS one.
[17] N. Pedemonte,et al. Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling. , 2011, American journal of physiology. Cell physiology.
[18] P. Kris-Etherton,et al. Development of a cell-based, high-throughput screening assay for cholesterol efflux using a fluorescent mimic of cholesterol. , 2011, Assay and drug development technologies.
[19] Zahida Parveen,et al. Molecular Dissection of Dual Pseudosymmetric Solute Translocation Pathways in Human P-Glycoprotein , 2011, Molecular Pharmacology.
[20] Jan Ellenberg,et al. Micropilot: automation of fluorescence microscopy–based imaging for systems biology , 2011, Nature Methods.
[21] A. Holzinger,et al. Some ABCA3 mutations elevate ER stress and initiate apoptosis of lung epithelial cells , 2011, Respiratory research.
[22] J. Lehár,et al. Identification of synergistic combinations of F508del cystic fibrosis transmembrane conductance regulator (CFTR) modulators. , 2010, Assay and drug development technologies.
[23] C. Harding. New era in treatment for phenylketonuria: Pharmacologic therapy with sapropterin dihydrochloride , 2010, Biologics : targets & therapy.
[24] J. Riordan,et al. Modulation of endocytic trafficking and apical stability of CFTR in primary human airway epithelial cultures. , 2010, American journal of physiology. Lung cellular and molecular physiology.
[25] E. Boerwinkle,et al. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout , 2009, Proceedings of the National Academy of Sciences.
[26] Balázs Sarkadi,et al. Ins and outs of the ABCG2 multidrug transporter: an update on in vitro functional assays. , 2009, Advanced drug delivery reviews.
[27] J. Riordan,et al. CFTR function and prospects for therapy. , 2008, Annual review of biochemistry.
[28] Tudor I. Oprea,et al. High-throughput flow cytometry to detect selective inhibitors of ABCB1, ABCC1, and ABCG2 transporters. , 2008, Assay and drug development technologies.
[29] Richard J. Thompson,et al. Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families. , 2008, Gastroenterology.
[30] B. Sarkadi,et al. Combined localization and real-time functional studies using a GFP-tagged ABCG2 multidrug transporter. , 2008, Biochemical and biophysical research communications.
[31] Tudor I. Oprea,et al. High-Throughput Screening for Daunorubicin-Mediated Drug Resistance Identifies Mometasone Furoate as a Novel ABCB1-Reversal Agent , 2008, Journal of biomolecular screening.
[32] G. Szakács,et al. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. , 2006, Physiological reviews.
[33] James Rader,et al. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. , 2006, American journal of physiology. Lung cellular and molecular physiology.
[34] J. Lupski,et al. ABCA4 mutations causing mislocalization are found frequently in patients with severe retinal dystrophies. , 2005, Human molecular genetics.
[35] G. Lukács,et al. Antibodies for CFTR studies. , 2004, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[36] Y. Sugiyama,et al. Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. , 2002, Advanced drug delivery reviews.
[37] Zhe-Sheng Chen,et al. Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). , 2002, Cancer research.
[38] B. Sarkadi,et al. Loss of ATP-dependent Transport Activity in Pseudoxanthoma Elasticum-associated Mutants of Human ABCC6 (MRP6)* , 2002, The Journal of Biological Chemistry.
[39] B. Rothen‐Rutishauser,et al. P-Glycoprotein in cell cultures: a combined approach to study expression, localisation, and functionality in the confocal microscope. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[40] N. Dokholyan,et al. Correctors of F508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein , 2014 .
[41] I. Ieiri. Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). , 2012, Drug metabolism and pharmacokinetics.
[42] B. Sarkadi,et al. Mitoxantrone is expelled by the ABCG2 multidrug transporter directly from the plasma membrane. , 2011, Biochimica et biophysica acta.
[43] G. Lukács,et al. CFTR Folding Consortium: methods available for studies of CFTR folding and correction. , 2011, Methods in molecular biology.
[44] C. Conrad,et al. Functional genomics assays to study CFTR traffic and ENaC function. , 2011, Methods in molecular biology.